Table 3 |
|||||||||||||
|
Baseline and 3-month and 6-month tocilizumab therapy criteria in 13 patients with axial spondyloarthritis |
|||||||||||||
|
Pt 1 |
Pt 2 |
Pt 3 |
Pt 4 |
Pt 5 |
Pt 6 |
Pt 7 |
Pt 8 |
Pt 9 |
Pt 10 |
Pt 11 |
Pt 12 |
Pt 13 |
|
|
|
|||||||||||||
|
BASDAI, 0 to 100 |
|||||||||||||
|
M0 |
78 |
90 |
72 |
42 |
77 |
63 |
80 |
48 |
49 |
59 |
48 |
72 |
57 |
|
M3 (change from M0; %) |
+6 |
-19 |
+1 |
-15 |
+1 |
-1.6 |
+3.8 |
-2 |
+4 |
-5 |
+43 |
-10 |
-12 |
|
M6 (change from M0; %) |
NA |
NA |
NA |
-17 |
NA |
NA |
NA |
NA |
-6 |
-15 |
+17 |
NA |
NA |
|
ASDAS |
|||||||||||||
|
M0 |
4.87 |
3.35 |
3.24 |
3.37 |
5 |
5.36 |
3.8 |
2.98 |
2.68 |
2.41 |
2.94 |
3.2 |
4.12 |
|
M3 (change from M0; units) |
-1.6 |
-0.8 |
-0.75 |
-0.04 |
-1.5 |
-1.7 |
-0.3 |
-0.24 |
-1.36 |
-0.43 |
-0.35 |
+0.02 |
-1.96 |
|
M6 (change from M0; units) |
NA |
NA |
NA |
-1.17 |
NA |
NA |
NA |
NA |
-1.02 |
-0.61 |
-0.23 |
NA |
NA |
|
BASFI, 0 to 100 |
|||||||||||||
|
M0 |
86 |
95 |
63 |
32 |
72 |
MD |
MD |
59.5 |
50 |
57 |
59 |
28 |
36 |
|
M3 (change from M0; %) |
-8 |
-8 |
+16 |
+3 |
+28 |
MD |
MD |
-6 |
+6 |
-7 |
+30 |
-29 |
+47 |
|
M6 (change from M0; %) |
NA |
NA |
NA |
+22 |
NA |
MD |
MD |
NA |
0 |
-7 |
-34 |
NA |
NA |
|
Pain VAS, 0 to 10 |
|||||||||||||
|
M0 |
9 |
10 |
7 |
4 |
7 |
7 |
8 |
4 |
5 |
6 |
5 |
7 |
4 |
|
M3 (change from M0; units) |
+0.5 |
-3 |
+1 |
0 |
0 |
-0.2 |
+1 |
+3 |
+1 |
-2 |
0 |
-1 |
0 |
|
M6 (change from M0; units) |
NA |
NA |
NA |
-1 |
NA |
NA |
NA |
NA |
+1 |
-2 |
+2 |
NA |
NA |
|
CRP (mg/dl)a |
|||||||||||||
|
M0 |
29 |
0 |
2 |
46 |
35 |
96 |
10 |
10.4 |
1 |
1 |
1.8 |
3 |
35.2 |
|
M3 (absolute value) |
0.3 |
0 |
0 |
NA |
3 |
4 |
1 |
< 5 |
NA |
NA |
NA |
3 |
1 |
|
M6 (absolute value) |
NA |
NA |
NA |
6 |
NA |
NA |
NA |
NA |
0 |
1 |
0.6 |
NA |
NA |
|
ESR (mm)a |
|||||||||||||
|
M0 |
71 |
9 |
8 |
47 |
35 |
104 |
21 |
12 |
9 |
8 |
1 |
11 |
15 |
|
M3 (absolute value) |
10 |
2 |
4 |
NA |
2 |
2 |
1 |
3 |
NA |
NA |
NA |
3 |
1 |
|
M6 (absolute value) |
NA |
NA |
NA |
5 |
NA |
NA |
NA |
NA |
4 |
1 |
1 |
NA |
NA |
|
|
|||||||||||||
|
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS, Assessment of SpondyloArthritis International Society-endorsed disease activity score; BASFI, Bath Ankylosing Spondylitis Functional Index; VAS, visual analogue scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; M0, month 0 (baseline); M3, month 3; M6, month 6; MD, missing data; NA, not available; Pt, Patient. aFor CRP and ESR, the table shows only the values at baseline (M0) and at last follow-up (M3 or M6). |
|||||||||||||
|
Lekpa et al. Arthritis Research & Therapy 2012 14:R53 doi:10.1186/ar3766 |
|||||||||||||
